Dapagliflozin’s impact on health-related quality of life and mortality in patients of chronic heart failure with reduced ejection fraction: a randomized controlled trial
Objective: To explore the impact of dapagliflozin on health-related quality of life, functional status and mortality in chronic heart failure with reduced ejection fraction patients. Method: The randomized controlled trial was conducted from April 2023 to May 2024 at the Department of Pharmacology and Therapeutics, Arm...